For Campus Prearrival Information <click here>
For a PDF of the 2015 Program Materials <click here>
For ALL Abstracts [1-220] in sequential order <click here>
For ALL Authors of the Lecture and Poster Presentations <click here>
The mitochondrial permeability transition pore (mtPTP) is a Ca2+-requiring megachannel that permanently opens under pathological conditions and leads to deregulated release of Ca2+ and mitochondrial dysfunction. For the past couple of decades the mtPTP has been implicitly recognized as a therapeutic target for several deadly diseases such as Alzheimer’s disease, muscular dystrophies, myocardial infarction, stroke, and diabetes. Herein we report the results of a high-throughput screening/chemical optimization approach that led to the discovery of two new chemotypes: (a) diarylisoxazole-3-carboxamides and (b) N-phenylbenzamides, which are first subnanomolar inhibitors of the mtPTP. The therapeutic potential and in vivo efficacy of the most potent analogues were validated in a biologically relevant zebrafish model of collagen VI congenital muscular dystrophies.